↓ Read PDF
01 · ABSTRACT

Abstract

Purpose: In 15 previously healthy cases who developed osteonecrosis, 4 months after Covid, 14 primary, 1 secondary), we prospectively addressed 2 hypotheses. First, Covid-19-associated coagulopathy superimposed on underlying previously undiagnosed familial thrombophilia-hypofibrinolysis leads to development of severe multifocal osteonecrosis (Ficat Stage III-IV ON 0.25-12 months after Covid-19). Second, joint pain can be relieved and joint collapse prevented by anticoagulation (Xarelto or Eliquis) before joint collapse in osteonecrosis with underlying familial coagulopathies.

Basic Procedure: Thrombophilia-hypofibrinolysis measures in 15 cases were compared to 110 healthy controls and to 235 patients with primary osteonecrosis without Covid.

Main Findings: Post-Covid osteonecrosis developed in both hips- all 15 cases, both knees-4 cases, multifocal- 4 cases. Four months (median) post- Covid, all 30 hips were painful, 10 Ficat stage I,10 II, 6 III, and 4 IV. Cases were more likely to have Factor V Leiden heterozygosity, (4/15 [27%] than controls (2/109 (2%) (p=.002) and primary ON cases (21/235 (9%) (p<.05. Cases were more likely (6/15, 40%) to have V Leiden and/or Prothrombin G20210A heterozygosity than both 3/110 (3%) healthy controls (p=.0001). and 30/231 (13%) primary ON cases, p=.012. In 9 cases, of 18 joints Ficat stage I or II pre-anticoagulation, given Eliquis or Xarelto for 1 year (median), 0/18 joints collapsed, pain resolved  joints- 6 cases), and improved (6 joints- 3 cases).

Principal Conclusions: Post-Covid osteonecrosis joint pain should trigger evaluation for underlying familial coagulopathies, and consideration of anticoagulation in early primary osteonecrosis (Ficat stages I-II).  

New-Important: Anticoagulation  before osteonecrosis joint collapse in post Covid patients with familial coagulopathies can relieve pain and prevent joint collapse.  

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 14 No 8 (2026): Vol 14 Issue 8 August 2026
SectionResearch Articles
Published01 September 2026
DOI10.18103/mra.v14i8.7783
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

Charles J. Glueck

The Cholesterol, Metabolism, and Thrombosis Research Center, 3906 Middleton Ave, Cincinnati OH 45220

ORCID
Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗